【港股通】山东新华制药股份恩格列净片获国家药督局注册批准 适用于治疗2型糖尿病

金吾资讯
21 Jan

金吾财讯 | 山东新华制药股份(00719)公布,近日公司收到国家药品监督管理局核准签发的恩格列净片(10mg)《药品注册证书》,本品符合药品注册的有关要求,批准注册。恩格列净片适用于治疗2型糖尿病;用于症状性慢性心力衰竭成人患者,降低因心力衰竭住院的风险。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10